Michael Mark

Medicine · Health Sciences

17h-index1.2kcitations97works1.42yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(35), Lung Cancer Research Studies(19), Lung Cancer Diagnosis and Treatment(16), Cancer Immunotherapy and Biomarkers(14), Bone health and treatments(11)

Publications97 total

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19).
Open Access CRIS of the University of Bern·2026Open Access
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19)
European Journal of Cancer·2025Open Access
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases
Lung Cancer·2025Open Access
EP.06.83 Prognostic Impact of PD-L1 Expression in a Swiss Cohort ofEGFR-Mutant Non-Small Cell Lung Cancer Patients Treated With First-Line Osimertinib
Journal of Thoracic Oncology·2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
Nature Communications·2025Open Access
2970P SLFN11 expression as potential prognostic marker in pleural mesothelioma
Annals of Oncology·2025
1835P Prognostic role of exosome in patients with stage IIIA(N2) non-small cell lung cancer treated with perioperative durvalumab in addition to neoadjuvant chemotherapy in the trial SAKK 16/14
Annals of Oncology·2025
Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study
Clinical Lung Cancer·2025
Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After Neoadjuvant Treatment—A Retrospective Analysis of the SAKK Trials 16/96, 16/00, 16/01, 16/08, and 16/14: A Brief Report
JTO Clinical and Research Reports·2025Open Access
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland
Swiss Medical Weekly·2025· 1 citedOpen Access
First-line immunotherapy +/- chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small Cell Lung Cancer (NSCLC) with asymptomatic brain metastases
SSRN Electronic Journal·2025Open Access
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Study
JTO Clinical and Research Reports·2024· 4 citedOpen Access
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
JTO Clinical and Research Reports·2024· 5 citedOpen Access
1791P Thoracic radiotherapy plus maintenance durvalumab after first-line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ED-SCLC): A multicenter single-arm open-label phase II trial (SAKK 15/19)tle
Annals of Oncology·2024Open Access
Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison
Supportive Care in Cancer·2024· 4 citedOpen Access
Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study
Bone Reports·2024· 2 citedOpen Access
Incidence of osteonecrosis of the jaw (ONJ) in the randomized non-inferiority phase III trial SAKK 96/12 REDUSE comparing denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w).
Journal of Clinical Oncology·2024· 1 cited
Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer
Lung Cancer·2024· 7 cited
484: SAKK 16/18: QA and interim safety of immune-modulatory RT in resectable stage III(N2) NSCLC
Radiotherapy and Oncology·2024
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Roger von Moos(18), Martin Früh(17), Sacha I. Rothschild(16), Patrizia Froesch(13), Miklos Pless(13), Richard Cathomas(11), Christine Waibel(11), Markus Joerger(10), E.I. Eboulet(9), Sabine Schmid(9), Walter H. Reinhart(9), Yannis Metaxas(9), Laetitia Mauti(8), Solange Peters(8), Alfredo Addeo(8), Daniel Betticher(7), Roland B. Walter(7), Stefanie Hayoz(7), Adrienne Bettini(6), Christian Britschgi(6)